Home Cart Sign in  
Chemical Structure| 1232410-49-9 Chemical Structure| 1232410-49-9

Structure of VE-821
CAS No.: 1232410-49-9

Chemical Structure| 1232410-49-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 values of 13 nM/26 nM.

Synonyms: ATR Inhibitor IV

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of VE-821

CAS No. :1232410-49-9
Formula : C18H16N4O3S
M.W : 368.41
SMILES Code : O=C(C1=NC(C2=CC=C(S(=O)(C)=O)C=C2)=CN=C1N)NC3=CC=CC=C3
Synonyms :
ATR Inhibitor IV
MDL No. :MFCD19443686
InChI Key :DUIHHZKTCSNTGM-UHFFFAOYSA-N
Pubchem ID :51000408

Safety of VE-821

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of VE-821

DNA
PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • ATR

    ATR, Ki:13 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
UWB1 + B1 0.313 µM 6 days VE-821 significantly reduced the IC50 of PARPi (olaparib) in resistant cells, indicating that ATRi can preferentially sensitize PARPi-resistant BRCA1-deficient cells to PARPi. Genes Dev. 2017 Feb 1;31(3):318-332.
SYr12 0.313 µM 6 days VE-821 significantly reduced the IC50 of PARPi (olaparib) in resistant cells, indicating that ATRi can preferentially sensitize PARPi-resistant BRCA1-deficient cells to PARPi. Genes Dev. 2017 Feb 1;31(3):318-332.
SYr13 0.313 µM 6 days VE-821 significantly reduced the IC50 of PARPi (olaparib) in resistant cells, indicating that ATRi can preferentially sensitize PARPi-resistant BRCA1-deficient cells to PARPi. Genes Dev. 2017 Feb 1;31(3):318-332.
MHCC-97H cells 38.74 μM VE821 significantly inhibited the proliferation, migration, and colony formation ability of MHCC-97H cells and enhanced apoptosis J Exp Clin Cancer Res. 2022 Jan 8;41(1):17.
Hep3B cells 18.22 μM VE821 significantly inhibited the proliferation, migration, and colony formation ability of Hep3B cells and enhanced apoptosis J Exp Clin Cancer Res. 2022 Jan 8;41(1):17.
HeLa cells 10 μM 8 h To examine the effect of VE-821 on MSL1 mRNA isoforms, results showed that VE-821 did not block MSL1 upregulation. Cell Rep. 2021 Oct 12;37(2):109815.
U2OS cells 10 μM 8 h To examine the effect of VE-821 on MSL1 mRNA isoforms, results showed that VE-821 did not block MSL1 upregulation. Cell Rep. 2021 Oct 12;37(2):109815.
U2OS cells 10μM 24 h To investigate the effect of VE-821 on micronuclei rupture, results showed that VE-821 reduced the fraction of cGAS+ micronuclei Mol Cell. 2023 Oct 19;83(20):3642-3658.e4.
MDA-MB-231 cells 10μM 24 h To investigate the effect of VE-821 on micronuclei rupture, results showed that VE-821 reduced the fraction of cGAS+ micronuclei Mol Cell. 2023 Oct 19;83(20):3642-3658.e4.
HeLa cells 10μM 24 h To investigate the effect of VE-821 on micronuclei rupture, results showed that VE-821 reduced the fraction of cGAS+ micronuclei Mol Cell. 2023 Oct 19;83(20):3642-3658.e4.
AGS cells 1 μM, 2 μM, 5 μM 72 h VE-821 significantly inhibited the proliferation of AGS cells and synergized with cisplatin to enhance its sensitivity. Transl Oncol. 2023 Oct;36:101743.
MKN-45 cells 1 μM, 2 μM, 5 μM 72 h VE-821 significantly inhibited the proliferation of MKN-45 cells and synergized with cisplatin to enhance its sensitivity. Transl Oncol. 2023 Oct;36:101743.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Immunodeficient mice Hepatocellular carcinoma xenograft model Intraperitoneal injection 15 mg/kg Twice a week for 20 days VE821 significantly inhibited tumor growth in the hepatocellular carcinoma xenograft model without showing significant toxicity J Exp Clin Cancer Res. 2022 Jan 8;41(1):17.
BALB/c nude mice Gastric cancer xenograft model Oral VE-821, intraperitoneal cisplatin 3 mg/kg Every three days for three weeks Combination of VE-821 and cisplatin significantly inhibited tumor growth and increased the expression of DNA damage marker γ-H2AX. Transl Oncol. 2023 Oct;36:101743.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.57mL

2.71mL

1.36mL

27.14mL

5.43mL

2.71mL

References

 

Historical Records

Categories